Effectiveness of direct delabelling of allergy labels in type A adverse drug reactions to penicillin: a multicentre hospitalwide prospective cohort study
Journal of Antimicrobial Chemotherapy · 01.10.2024 · 79 (10) · 2640-2644
DOI: 10.1093/jac/dkae270 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 30.07.2024. Verfasst von Kate Drummond und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia. Hauptthemen laut MEDLINE: Penicillins, Drug Hypersensitivity, Anti-Bacterial Agents, Drug Labeling. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
Patient-reported penicillin allergy labels (PALs) are associated with adverse patient outcomes and inappropriate antibiotic prescribing. Removal of PALs via direct oral challenge (DOC) is associated with increased penicillin utilization post removal.
Objectives
To assess the impact of direct delabelling (allergy label removal via medical reconciliation alone) of type A adverse drug reaction (ADR) PALs on inpatient prescribing.
Methods
From January 2019 to December 2022 at two tertiary hospitals in Melbourne, patients aged ≥18 years with type A ADR PALs, as defined by the validated Antibiotic Allergy Assessment Tool, were offered direct delabelling or single-dose DOC. The primary endpoint was antibiotic use pre- and post-assessment (during index admission and 90 days post assessment). The secondary endpoint was the proportion of patients delabelled in the direct delabelling and DOC cohorts in the electronic medical record at 90 days post assessment.
Results
Allergy labels (n = 4108) were assessed for 488 participants, with 490 individual type A ADR PAL assessments included. Three hundred and thirty-seven patients were directly delabelled, 69 underwent DOC and 84 were not delabelled. There was increased use of any penicillin following direct delabelling (OR 19.19, 95% CI 2.48–148.36) and DOC (OR 56.98, 95% CI 6.82–476.19) during the index admission, higher in the DOC group compared with direct delabelling (OR 2.97, 95% CI 1.39–6.37). Relabelling at 90 days was low with no statistically significant difference between direct delabelling (5/337; 1.5%) and DOC (0/69; 0%).
Conclusions
Both direct delabelling and DOC of type A ADR PALs increased penicillin usage; however, the impact was greatest with DOC. Most patients remain delabelled at 90 days.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.
- Department of Infectious Diseases, The Peter Doherty Institute of Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
- Department of Medicine, St Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
- Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
ORCID-Profile: Kate Drummond, Sara Vogrin, Jason A Trubiano, Elise Mitri
Zitieren
APA
Drummond, K., Vogrin, S., Lambros, B., Trubiano, J. A., & Mitri, E. (2024). Effectiveness of direct delabelling of allergy labels in type A adverse drug reactions to penicillin: a multicentre hospitalwide prospective cohort study. Journal of Antimicrobial Chemotherapy, 79(10), 2640-2644. https://doi.org/10.1093/jac/dkae270
Vancouver
Drummond K, Vogrin S, Lambros B, Trubiano JA, Mitri E. Effectiveness of direct delabelling of allergy labels in type A adverse drug reactions to penicillin: a multicentre hospitalwide prospective cohort study. Journal of Antimicrobial Chemotherapy. 2024;79(10):2640-2644. doi:10.1093/jac/dkae270
BibTeX
@article{Drummond2024,
author = {Drummond, Kate and Vogrin, Sara and Lambros, Belinda and Trubiano, Jason A and Mitri, Elise},
title = {Effectiveness of direct delabelling of allergy labels in type A adverse drug reactions to penicillin: a multicentre hospitalwide prospective cohort study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {10},
pages = {2640--2644},
doi = {10.1093/jac/dkae270}
}
EUVIMED